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A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in patients with advanced transitional cell
carcinoma (TCC) of the bladder; secondary objectives were to assess duration of response, progression-free survival (PFS) and
overall survival (OS), and to evaluate the toxicity associated with this treatment. Patients had tumours that failed or progressed after
first-line platinum-containing regimens for advanced or metastatic disease, or had progressive disease after platinum-containing
chemotherapy given with adjuvant or neoadjuvant intent. Response and adverse events were assessed according to WHO criteria
and NCI-CTC (version 2), respectively. Out of 51 patients treated with 320mgm
 2 of vinflunine, nine patients responded to the
therapy yielding an overall response rate of 18% (95% CI: 8.4–30.9%), and 67% (95%CI: 52.1–79.3%) achieved disease control
(PRþSD). Of note, responses were seen in patients with relatively poor prognostic factors such as a short (o12 months) interval
from prior platinum therapy (19%, including an 11% response rate in those progressing o3 months after platinum treatment), prior
treatment for metastatic disease (24%), prior treatment with vinca alkaloids (14%) and visceral involvement (20%). The median
duration of response was 9.1 months (95% CI: 4.2–15.0) and the median PFS was 3.0 months (95% CI: 2.4–3.8). The median OS
was 6.6 months (95% CI: 4.8–7.6). The main haematological toxicity was grade 3–4 neutropenia, observed in 67% of patients (42%
of cycles). Febrile neutropenia was observed in five patients (10%) and among them two were fatal. Constipation was frequently
observed (but was manageable and noncumulative) and was grade 3–4 in only 8% of patients. The incidence of grade 3 nausea and
vomiting was very low (4 and 6% of patients, respectively). Neither grade 3–4 sensory neuropathy nor severe venous irritation was
observed. Moreover, and of importance in this particular study population, no grade 3–4 renal function impairment was observed.
Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in
phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.
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Before the development of effective chemotherapy, median
survival of patients with metastatic bladder cancer rarely exceeded
4 months. Treatment with cisplatin, approved for the treatment of
advanced disease in the early 1980s, doubled median survival to 8
months (Loehrer et al, 1992).
The combination regimen including methotrexate, vinblastine,
doxorubicin and cisplatin (M-VAC) was devised at Memorial
Sloan-Kettering in the mid 1980s (Sternberg et al, 1988) and
improved overall survival to a median slightly in excess of 12
months and became the standard of care worldwide for advanced
bladder cancer (Culine, 2002).
Gemcitabine was developed in the late 1990s and, as a single
agent, produced objective response rates ranging from 11 to 29%
in second-line (Lorusso et al, 1988; Gebbia et al, 1999; Albers et al,
2002), and of 24–45% in first-line therapy (Moore et al, 1997;
Stadler et al, 1997; Castagneto et al, 2004). A combination regimen
of cisplatin and gemcitabine was developed and compared with
M-VAC, producing comparable efficacy results, and a reduction of
side effects (most notably severe mucositis and infections, as well
as alopecia) (Von Der Maase et al, 2000). Based on these results,
gemcitabine (in combination with cisplatin) received regulatory
approval for the first-line treatment of advanced bladder cancer in
the European Union as well as in several other countries. Although
not approved in the US, the gemcitabine/cisplatin regimen has
been widely adopted for this indication.
Recent years have witnessed the establishment of neoadjuvant
chemotherapy as a treatment modality superior in survival to
surgery or radiotherapy alone for muscle-invasive bladder cancer,
and this observation is currently supported by large randomised
trials as well as by meta-analyses (Meta-Analysis, 2003). Owing to
this, and not dissimilarly from other tumours, the most active
agents and combinations are currently employed in early stages of
the disease.
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sFor patients whose disease relapses or progression after initial
treatment limited options exist and new active drugs are needed.
Vinflunine ditartrate (Javlor
s, Pierre Fabre Me ´dicament,
Boulogne-Billancourt – France) is a novel antitubulin agent
obtained by a semisynthetic process from a vinca alkaloid base
showing higher antitumour activity compared with parent
compounds.
Vinflunine showed definite (high or moderate) antitumour
activity in 64% (seven out of 11) of xenografts tested, compared
with vinorelbine which showed only moderate activity in
27% (three out of 11) (Kruczynski et al, 1998a, b; Hill et al,
1999). Furthermore, a preclinical study effects of vinflunine
on a murine bladder cancer cell line (MB-49) showed clear
cytotoxic activity (Bonfil et al, 2002). Vinflunine was thus
considered a good candidate for further clinical study in bladder
cancer.
Single agent vinflunine was studied in several clinical phase I
trials utilising different schedules (Delord et al, 2001; Bennouna
et al, 2003; Johnson et al, 2005), leading to the selection of the 3
weekly schedule for phase II evaluation.
PATIENTS AND METHODS
Objectives
This study was an open-label, multicentre, noncomparative
phase II trial designed to determine the efficacy of vinflunine
in patients with advanced transitional cell carcinoma (TCC) of
the bladder previously treated with one platinum-based line
of chemotherapy. The primary objective was to assess efficacy
in terms of tumour response rate; secondary objectives were
to assess duration of response, progression-free survival (PFS)
and overall survival (OS), and to evaluate the treatment related
toxicity.
The protocol and its amendments were submitted to Indepen-
dent Ethics Committees according to local requirements. The
study was conducted in accordance with the ethical principles set
forth in the Declaration of Helsinki and in compliance with Good
Clinical and Laboratory Practices. Written informed consent was
obtained before entry into the study.
Patient selection
A total sample size of 50 evaluable patients was calculated using
the 1-sample multiple testing procedure of Fleming for phase II
clinical trials (Fleming, 1982). A small excess in recruitment was
allowed to replace possible dropouts.
Patients were recruited from 16 European centers between
November 2000 and September 2002. Eligible patients had
histologically proven TCC of the bladder, which had failed or
progressed after first-line platinum-containing regimens for
advanced or metastatic disease, or treatment given with adjuvant
or neoadjuvant intent. Previous systemic chemotherapy or radio-
therapy had to have been stopped 30 days before the administra-
tion of the study drug with full recovery from all severe side effects.
The presence of at least one bidimensionally measurable lesion,
not previously irradiated, assessed by CT-scan or MRI performed
o28 days before first day of study drug administration was
required. Patients were required to be aged X18 years with
Karnofsky performance status (KPS) X80 and an estimated life
expectancy X12 weeks with adequate haematological function
(absolute neutrophil count X2.0 10
9l
 1, platelets
X100 10
9l
 1), hepatic function (bilirubin p1.5  upper normal
limit (UNL), transaminases p2.5  UNL, unless due to liver
involvement), renal function (calculated clearance of creatinine
X40mlmin
 1, Cockcroft-Gault formula) and a normal electro-
cardiogram (ECG).
Treatment schedule
Patients were treated at the beginning of study with intravenous
(i.v.) vinflunine 350mgm
 2 as a 10min infusion 3 weekly based on
the previous phase I trial (Bennouna et al, 2003). A preliminary
safety evaluation, performed programwide across all ongoing
vinflunine phase II trials, led to a dose reduction to 320mgm
 2 3
weekly (the next lower dose level of the preceding phase I trial).
Tolerance was assessed throughout the treatment period and
before each administration according to the NCI Common
Toxicity Criteria (Version 2.0). All patients who received at least
one cycle were considered evaluable for safety. The use of
haematopoietic growth factors (G-CSF) was allowed for patients
with febrile neutropenia or neutropenic infections.
Vinflunine administration was delayed by 1 or 2 weeks in
the case of significant haematological or nonhaematological
toxicity (grade 42 toxicity impacting a major organ except for
alopecia).
If febrile neutropenia and/or grade 4 neutropenia
(o0.5 10
9l
 1) lasting X7 days was observed between two
subsequent administrations of vinflunine, the dose was reduced
to 280mgm
 2 from the next cycle on. If, after dose reduction,
this toxicity was seen again, the dose was further reduced to
250mgm
 2. If at this dose level the same event recurred, the
treatment was stopped. Blood counts were performed every 2 days
until recovery of ANC X1.0 10
9l
 1. No dose re-escalation was
allowed after dose reduction. In case of grade 2 mucositis and/or
constipation lasting 45 days, or grade X3 mucositis, and/or
constipation of any duration, the vinflunine dose was reduced to
280mgm
 2 from the next cycle on. If, after dose reduction, one
of these toxicities was seen again, the dose was reduced to
250mgm
 2. If at this dose the event recurred, the treatment was
discontinued. Each patient received at least two cycles of treatment
unless one of the following occurred: early progression, unac-
ceptable toxicity, serious intercurrent illness, other reactions which
could affect the clinical status of the patient to a significant degree
requiring discontinuation of the drug, or request by the patient to
withdraw consent.
After the initial two cycles, tumour response was assessed.
Patients with progressive disease (PD) discontinued treatment;
those with stable disease (s.d.) received two additional cycles of
vinflunine, were assessed a second time and treatment was
continued according to the Investigator’s opinion. Complete or
partial responders (CR, PR) could continue treatment either until
PD, toxicity or patient preference precluded further therapy.
Baseline and treatment evaluation
Preregistration assessments included a detailed medical history,
physical examination, CT or MRI scan. All positive imaging
procedures at study entry were repeated every 6 weeks. An
assessment of symptoms was made at study entry and then
throughout treatment. Physical examination and vital signs were
assessed on day 1 of each cycle. A complete blood cell count was
performed at baseline (within 7 days of drug administration),
before each cycle and at days 8 and 15 of each cycle, repeated every
2 days if the ANC was o1.0 10
9l
 1 until recovery to ANC
X1.0 10
9l
 1. Transaminases, alkaline phosphatase, total bili-
rubin, creatinine, electrolytes and total protein were assessed at
every cycle. An ECG was performed at baseline and repeated every
cycle.
If a patient did not progress by the end of the study, all lesions
were regularly assessed until either the patient progressed or
started other anticancer therapy. Response was assessed using
the WHO criteria (WHO Handbook, 1979; SWOG, 1992). In order
to be confirmed, CR and PR were to be maintained for at least 4
weeks, while no other type of lesion progressed or appeared. All
responses and disease stabilisations were individually reviewed
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sand confirmed by an independent radiologist, as stipulated by the
study protocol.
According to WHO criteria, the duration of response was
calculated for patients with confirmed response (CR or PR) from
the date of registration until the date of documented progression,
death, last follow-up or last news. Any responding patient alive
without progression was censored at the date of commencement of
new treatment or at last contact. Progression-free survival was
defined as the time elapsed from registration until progression,
death, lost follow-up or last information available. Progression-free
survival of patients alive without progression was censored at the
date of last information. Survival was defined as the time elapsed
from registration to death or lost follow-up. The statistical analysis
was performed on an intent-to-treat (ITT) basis on all patients
registered and treated.
RESULTS
In total, 58 patients with advanced or metastatic TCC of the
bladder were included in this study. One patient died before
receiving any treatment, hence was not included in the analysis.
Six patients treated initially at 350mgm
 2 represent too small a
group to justify an extensive separate analysis, therefore results are
focused on the 51 patients treated at 320mgm
 2, the majority of
whom (84%) relapsed or progressed within 12 months of initial
chemotherapy.
Demographic features are summarised in Table 1. Prior therapy
included surgery, radiotherapy, or local bladder instillations of
either chemotherapy or BCG and all had received systemic
platinum-based chemotherapy; 22 patients (43%) received M-
VAC or CMV and 25 patients (49%) gemcitabine/platinum
(Table 2). Prior chemotherapy was for advanced disease in 34
patients (67%) and as adjuvant or neoadjuvant chemotherapy in
17 patients (33%) (Table 3). The median treatment-free interval
between completion of initial chemotherapy and vinflunine
treatment was 7.5 months (range: 0.9–94.3). All patients enrolled
in the study had clear evidence of PD, 61% had two or more
metastatic lesions at entry and 49% had visceral involvement.
Efficacy evaluation
Among the 51 patients treated at 320mgm
 2, nine obtained a
partial response (18% (95% CI: 8.4–30. 9%) and 25 achieved s.d.,
for an overall disease control rate (PRþs.d.) of 67% (95% CI:
52.1–79.3%). Three patients could not be evaluated for response,
but are kept in the denominator for the purpose of the calculation
of the response rate (Table 4).
Disease control rates appeared to correlate with the interval
from prior platinum treatment, with better results in late relapsing
or progressing patients. Objective response rates were eight out of
34 (24%) and one out of 17 (6%) in patients previously treated in
the metastatic and neoadjuvant/adjuvant setting, respectively.
Of note, objective responses were observed in three out of 22
(14%) patients who had received prior vinca alkaloids as a
component of the M-VAC or CMV regimens.
Responses were predominantly seen in patients who had
previously responded to chemotherapy, although numbers are
too small to exclude random variation. However, five out of 25
(20%) of patients with visceral involvement achieved an objective
response and responses were seen in patients with primary chemo-
resistant disease (Table 5).
Of the six additional patients who started the trial at a dose of
350mgm
 2, only three were evaluable and none responded.
The median duration of response was 9.1 months (95% CI: 4.2–
15.0). Among the 51 patients treated at 320mgm
 2, the median
PFS was 3.0 months (95% CI: 2.4–3.8) and the median overall
survival was 6.6 months (95% CI: 4.8–7.6).
Karnofsky performance status was recorded for each patient at
baseline and before each treatment cycle during the study (every 3
Table 1 Demographic data
No. of patients (%): 51(100)
Age (years)
Median 63
Range (42–81)
Karnofsky performance status
100 12 (24)
90 16 (31)
80 22 (43)
70 1 (2)
Males 41 (80)
Females 10 (20)
Stage at diagnosis
Unknown 11 (22)
0IS 1 (2)
I 5 (10)
II 3 (6)
III 8 (16)
IV 23 (45)
Number of organs involved
1 20 (39)
2 19 (37)
X3 12 (24)
Lung only 7 (13.7)
Liver only 6 (11.8)
Bone only 1 (2.0)
Lymph nodes 34 (66.7)
Skin 2 (3.9)
Soft tissues 8 (15.7)
Lung+liver 9 (17.6)
Lung+bone 1 (2.0)
Liver+bone 2 (3.9)
Other organs 12 (23.5)
Table 2 Previous local anticancer therapies
Initial dose of vinflunine
Treatment 350mgm
 2 N (%) 320mgm
 2 N (%)
No. of patients 6 51
Surgery alone 5 (83.3) 31 (60.7)
Radiotherapy alone — 2 (3.9)
Surgery+radiotherapy 1 (16.6) 15 (29.4)
Table 3 Prior treatment
No. of patients (%) 51(100)
Systemic platinum chemotherapy 51 (100)
For metastatic disease 34 (67)
gemcitabine/platinum 17
M-VAC/CMV 13
Other platinum regimens 4
For neoadjuvant/adjuvant 17 (33)
gemcitabine/platinum 8
M-VAC/CMV 9
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sweeks). Of 51 (22%) patients, 11 demonstrated improvement in
performance status during treatment, and 27 (53%) maintained
their baseline status. Only 10 patients (20%) had a worsening
during treatment.
Safety evaluation
A total of 15 cycles were administered to six patients initially
treated at 350mgm
 2. The most frequent adverse events at this
dose included leucopenia, neutropenia and anaemia, which were
observed in all six patients (100%) with one fatal febrile
neutropenia.
The total number of cycles administered at 320mgm
 2 was 197
(median four cycles, range 1–12) with median relative dose
intensity of 95.5%. Of 51 (35%) patients (14% of cycles), 18 had
dose reductions with the majority from 320mgm
 2 to 280mgm
 2
affecting 14 of 146 cycles (10%). Dose reductions to the lowest
planned dose (250mgm
 2) occurred only in six cycles (4%).
During the study, 23 of 51 (45%) patients experienced grade 3–4
leucopenia (27% of cycles), with grade 3–4 neutropenia in 34
patients (67%) (42% of cycles) (Table 6), 10 (29%) of whom had
received radiotherapy in the pelvic area. The median nadir value
for leucocytes and neutrophils was 2.2 10
9l
 1 and 0.6 10
9l
 1,
respectively. The median cycle at which both leucocyte and
neutrophil nadirs occurred was the second cycle of treatment (on
days 7 and 12, respectively). The median duration of leucopenia
and neutropenia was 7 days. Anaemia was rarely severe; only 14%
of patients developed grade 3 toxicity (5% of cycles). The incidence
of thrombocytopenia was also low, only three (6%) patients
developed grade 3 thrombocytopenia (2% of cycles). Five patients
(10%) experienced febrile neutropenia and two of them died (both
had received multiple courses of vinflunine). Grade 3–4 neutro-
penia complicated with infection were observed in three (6%)
patients (1.5% of cycles). Two (4%) patients had grade 3–4
infections without neutropenia (1% of cycles).
Nonhaematological toxicities were manageable. Only 4% of
patients experienced grade 3 nausea and only 6% of patients
experienced grade 3 vomiting. In all, 141 cycles (72%) were
administered with prophylactic use of antiemetics according to
institution protocol. Among the 28% of cycles without prophyl-
actic antiemetics, neither severe nausea nor vomiting was observed.
Constipation occurred in 65% but was grade 3 in three patients
(6%) and grade 4, in only one (2%). Among these four patients
there was a strong association with previous abdominal surgery
and concomitant treatment with opioids and 5HT3 antagonists. No
cumulative effect was seen for constipation. Prophylactic laxative
therapy helped to reduce the incidence of this complication. Grade
3 myalgia and fatigue were observed in only 4 and 10% of patients,
respectively (1 and 3% of cycles). Grade 3–4 sensory neuropathy
was not observed and the overall incidence of grade 1–2 toxicity
was very low (8%) as were injection site reactions – two patients
(4%) had grade 1 or 2 injection site reactions related to vinflunine.
At baseline, 10 patients (20%) had grade 1 elevation of renal
function tests, which increased to grade 2 in one patient (Table 7).
Despite frequent baseline involvement of the liver by disease, grade
III–IV elevations of liver function tests were infrequent.
DISCUSSION
The treatment of relapse following systemic chemotherapy for
advanced or metastatic TCC is problematical. A variety of agents
have been studied including ifosfamide, taxanes, oxaliplatin,
pemetrexed and bortezomib and the results are summarised
below.
Ifosfamide had been studied in the past, and its phase II results
in previously treated patients (not all platinum pretreated) have
been somewhat inconsistent with response rates of 1 and of 20% in
two studies (Pronzato et al, 1997; Witte et al, 1997). Be that as it
may, its use has become less frequent, due to the renal toxicity of
Table 4 WHO response rate according to platinum-free interval of patients treated with 320mgm
 2
Platinum-free interval at study entry
ITT population o3 months 3–12 months X12 months
No. of patients (%) 51 (100%) 19 (100%) 24 (100%) 8 (100%)
Response rate 9 (18%) 2 (11%) 6 (25%) 1 (13%)
(95%CI : 8.4–30.9%) (95%CI : 1.3–33.1%) (95%CI : 9.8–46.7%) (95%CI : 0.3–52.7%)
Stable disease (SD) 25 (49%) 9 (47%) 11 (46%) 5 (63%)
Disease control 34 (67%) 11 (58%) 17 (71%) 6 (75%)
(95%CI : 52.1–79.3%) (95%CI : 33.5–9.8%) (95%CI : 48.9–87.4%) (95%CI : 34.9–96.8%)
Progressive disease (PD) 14 (28%) 6 (32%) 6 (25%) 2 (25%)
Nonevaluable (NE) 3 (6%) 2 (11%) 1 (4%) —
Table 5 Description of responders
Age
Previous
chemotherapy
Response to
previous
chemotherapy Site of disease
Response to
vinflunine Cycles total (N)
Time to first
response (months)
62 GC NC Lymph nodes PR 7 4.2
71 GC PD Lymph nodes+lung PR 6 1.3
76 CMV PR Lymph nodes PR 4 1.7
71 GC PR Lymph nodes+lung PR 8 1.3
50 GC PR Liver + lung PR 8 1.3
79 GC PR Liver + lung PR 6 2.1
64 M-VAC PR Lymph nodes PR 4 1.5
63 GC NA Lymph nodes PR 8 1.3
45 CMV + GC CR Lung PR 5 1.1
CMV¼cisplatin, methotrexate, vinblastine; GC¼gemcitabine, cisplatin; M-VAC¼methotrexate, vinblastine, adriamycin, cisplatin.
Vinflunine salvage therapy for bladder cancer
S Culine et al
1398
British Journal of Cancer (2006) 94(10), 1395–1401 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthe compound, a particular problem with bladder carcinoma
patients who have received prior platinum.
A review of the recent literature concerning phase II trials in this
population confirms that very limited options exist for patients
who have been previously treated with gemcitabine/platinum, M-
VAC or CMV combinations (Table 8). The taxanes (paclitaxel and
docetaxel) have been studied in this setting, and are frequently
used in clinical practice, as they have yielded objective response
rates of 5–13% with response durations of 3.0–7.4 months. Severe
myelosuppression (for docetaxel) and peripheral neurotoxicity
(for paclitaxel) are the most common side effects. Unfortunately,
when brought forward to the first-line setting, a combination of
docetaxel and cisplatin was proven inferior to M-VAC (Bamias
Table 6 NCI CTC adverse events related to the study drug
No. of evaluable pts (%) No. of evaluable cycles (%)
No¼51 N¼197*
Adverse events Overall incidence Grade 3 Grade 4 Overall incidence Grade 3 Grade 4
Haematological*
Anaemia 46 (90) 7 (14) — 169 (86) 10 (5) —
Leucopenia 43 (84) 14 (28) 9 (18) 152 (78) 41 (21) 12 (6)
Neutropenia 42 (82) 16 (31) 18 (35) 144 (74) 43 (22) 39 (20)
Thrombocytopenia 22 (43) 3 (6) — 77 (39) 4 (2) —
Febrile neutropenia 5 (10) 4 (8) 1 (2) 5 (3) 4 (2) 1 (1)
Infection
Infection+G 3/4 neutropenia 3 (6) 2 (4) 1 (2) 4 (2) 2 (1) 1 (1)
Infection without neutropenia 7 (14) — 2 (4) 10 (5) — 2 (1)
Nonhaematological gastrointestinal
Nausea 19 (37) 2 (4) — 36 (18) 2 (1) —
Vomiting 13 (226) 3 (6) — 23 (12) 3 (2) —
Constipation 33 (65) 3 (6) 1 (2) 63 (32) 3 (25) 1 (1)
Anorexia 4 (8) 1 (2) — 27 (14) — —
Dehydration 13 (26) — — 4 (2) 1 (1) —
Dysphagia/oesophagitis 2 (4) 1 (2) — 3 (2) 1 (1) —
Stomatitis 17 (33) 3 (6) — 34 (17) 3 (2) —
Flu-like symptoms
Fatigue 34 (67) 5 (10) — 93 (47 6 (3) —
Pain
Abdominal pain 19 (37) 4 (8) — 32 (16) 6 (3) —
Bone pain 6 (12) 2 (4) — 9 (5) 2 (1) —
Myalgia 9 (186) 2 (4) — 15 (8) 2 (1) —
Pain-other 4 (8) — — 5 (3) — —
Neurological
Syncope 1 (2) 1 (2) — 1 (1) 1 (1) —
Neuropathy-sensory 4 (8) — — 6 (3) — —
Dermatological
Alopecia 20 (39) NA NA 83 (42) NA NA
Injection site reaction 2 (4) — — 3 (2) — —
Weight loss 10 (20) 1 (2) — 35 (18) 4 (2) —
*One cycle was not evaluable for haematological toxicity.
Table 7 Renal and liver function changes on treatment
Laboratory
test
No. of
evaluable pts
Overall
incidence
(any grade) Grade 3 Grade 4
Serum
creatinine
50 11 (22) — —
Bilirubin 51 3 (6) 1 (2) 1 (2)
SGOT/AST 48 12 (25) 1 (2) —
SGPT/ALT 49 13 (27) 1 (2) —
Alkaline
phosphatase
49 25 (51) 5 (10) —
Table 8 Recent phase II trials of single agents in previously treated bladder cancer
Drug Author (ref.) No. of pts Evaluable pts CR PR % Duration (months) TTP (months) OS (months)
Paclitaxel Vaughn (2002) 31 31 — 3 10 2.2 7.2
Papamichael (1997) 14 14 1 7 7.4
Joly (2004) 45 37 — 2 5 3.0
Docetaxel McCaffrey (1997) 30 30 — 4 13 4.0 9.0
Oxaliplatin Moore (2003) 20 18 — 1 6
Lapatinib Wulfing (2005) 59 59 — 2 3
Bortezomib Sridhar (2005) 18 11 — — 0
Pemetrexed Sweeney (2003) 47 47 3 10 28 3.0 9.8
Vinflunine salvage therapy for bladder cancer
S Culine et al
1399
British Journal of Cancer (2006) 94(10), 1395–1401 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
set al, 2004), whereas similar randomised paclitaxel/platinum
combination trials were abandoned for poor accrual (Dreicer
et al, 2004).
Recent trials with a novel platinum analogue (oxaliplatin), a dual
targeted tyrosine kinase inhibitor (lapatinib) and a proteasome
inhibitor (bortezomib) have yielded unimpressive results. Inter-
esting results have been obtained with the multitargeted folate
inhibitor pemetrexed, which demonstrated a high response rate of
28%, including complete responses, although of a seemingly short
duration. The compound has been also studied in the first-line
setting as a single agent or in combination with gemcitabine,
yielding objective response rates of 33% and of 27%, respectively.
Main side effects consisted of fatigue and myelosuppression.
Studies have also evaluated combinations of chemotherapy and
biological agents, for example, gemcitabine has been studied in
combination with the farnesyl transferase inhibitor SCH66336 in
the second-line treatment of patients with advanced urothelial
tract cancer. Nine partial responses and one complete response
were achieved in 31 assessable patients and corresponded to an
overall response rate of 32.3% (95% CI: 17–51%) (Theodore et al,
2005). Further evaluation of combinations of this sort is clearly
warranted.
The results obtained with vinflunine suggest that this compound
could be among the most active agents available in this setting. The
level of antitumour activity observed must be interpreted in view
of the poor prognosis of the population studied, with a universal
prior platinum-containing pretreatment a large proportion had
had prior vinca alkaloid exposure, and the frequent presence of
extensive visceral disease involvement at trial entry.
Although vinflunine exerted some severe toxicity (most
importantly myelosup ion and constipation), these side effects
appeared to be mostly manageable. A positive aspect of vinflunine
for patients with advanced bladder cancer is its reduced potential
for renal toxicity and its low level of peripheral neurotoxicity,
which do not overlap with the known cisplatin side effects. Renal
impairment has been reported as the most important factor
preventing up to 40% of the patients with TCC of the bladder
from receiving active, cisplatin-containing treatment (Dash et al,
2005).
In conclusion, the results of the present study demonstrate that
vinflunine has clinically relevant activity with acceptable toxicity in
the treatment of patients with TCC of the bladder who have failed
prior platinum-containing systemic chemotherapy. Further in-
vestigation of vinflunine in advanced or metastatic TCC of
urothelium tract is warranted, and a phase III trial in the
second-line treatment of the disease has begun. In addition, the
exploration of the role of the compound in patients with earlier
stages of disease and/or renal function impairment is also of
interest.
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